Technical Analysis for TYME - Tyme Technologies, Inc.

Grade Last Price % Change Price Change
D 1.545 5.10% 0.08
TYME closed up 10.53 percent on Wednesday, April 21, 2021, on 36 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat
Historical TYME trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 5.10%
Crossed Above 200 DMA Bullish 5.10%
Outside Day Range Expansion 5.10%
Wide Bands Range Expansion 5.10%
Lower Bollinger Band Touch Weakness 5.10%
Oversold Stochastic Weakness 5.10%
200 DMA Resistance Bearish 16.17%
Wide Bands Range Expansion 16.17%
Below Lower BB Weakness 16.17%
Lower Bollinger Band Touch Weakness 16.17%
Older End-of-Day Signals for TYME ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 5 hours ago
Up 5% about 5 hours ago
Rose Above Previous Day's High about 7 hours ago
Rose Above 10 DMA about 7 hours ago
Up 3% about 7 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Tyme Technologies, Inc. Description

Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company's another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company's therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Life Sciences Drug Development Takeda Pharmaceutical Company Cancer Therapeutics Millennium Pharmaceuticals Luminant

Is TYME a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 4.9894
52 Week Low 0.85
Average Volume 5,049,151
200-Day Moving Average 1.42
50-Day Moving Average 2.00
20-Day Moving Average 1.64
10-Day Moving Average 1.52
Average True Range 0.15
ADX 24.17
+DI 14.63
-DI 27.90
Chandelier Exit (Long, 3 ATRs ) 1.68
Chandelier Exit (Short, 3 ATRs ) 1.76
Upper Bollinger Band 1.93
Lower Bollinger Band 1.35
Percent B (%b) 0.21
BandWidth 35.17
MACD Line -0.15
MACD Signal Line -0.13
MACD Histogram -0.0148
Fundamentals Value
Market Cap 191.35 Million
Num Shares 130 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -5.25
Price-to-Sales 0.00
Price-to-Book 9.07
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.79
Resistance 3 (R3) 1.76 1.64 1.73
Resistance 2 (R2) 1.64 1.56 1.65 1.71
Resistance 1 (R1) 1.55 1.51 1.60 1.58 1.70
Pivot Point 1.43 1.43 1.45 1.44 1.43
Support 1 (S1) 1.34 1.35 1.39 1.37 1.24
Support 2 (S2) 1.22 1.30 1.23 1.23
Support 3 (S3) 1.13 1.22 1.21
Support 4 (S4) 1.16